These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11083327)

  • 1. Qualifying change: a method for defining clinically meaningful outcomes of change score computation.
    Tractenberg RE; Jin S; Patterson M; Schneider LS; Gamst A; Thomas RG; Thal LJ
    J Am Geriatr Soc; 2000 Nov; 48(11):1478-82. PubMed ID: 11083327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
    Schneider LS; Clark CM; Doody R; Ferris SH; Morris JC; Raman R; Reisberg B; Schmitt FA
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S124-38. PubMed ID: 17135806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADCS Prevention Instrument Project: overview and initial results.
    Ferris SH; Aisen PS; Cummings J; Galasko D; Salmon DP; Schneider L; Sano M; Whitehouse PJ; Edland S; Thal LJ;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S109-23. PubMed ID: 17135805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent change score modeling as a method for analyzing the antidepressant effect of a psychosocial intervention in Alzheimer's disease.
    Werheid K; Köhncke Y; Ziegler M; Kurz A
    Psychother Psychosom; 2015; 84(3):159-66. PubMed ID: 25833732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes.
    Tractenberg RE; Weiner MF; Patterson MB; Gamst A; Thal LJ
    J Geriatr Psychiatry Neurol; 2002; 15(2):110-7. PubMed ID: 12083593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    Lopez OL; Becker JT; Saxton J; Sweet RA; Klunk W; DeKosky ST
    J Am Geriatr Soc; 2005 Jan; 53(1):83-7. PubMed ID: 15667381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do changes in specific cognitive functions predict changes in health-related quality of life in people with Alzheimer's disease?
    Bosboom PR; Almeida OP
    Int J Geriatr Psychiatry; 2014 Jul; 29(7):694-703. PubMed ID: 24273030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort.
    Gillette-Guyonnet S; Cortes F; Cantet C; Vellas B;
    J Nutr Health Aging; 2005; 9(2):69-73. PubMed ID: 15791348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.
    Yost KJ; Sorensen MV; Hahn EA; Glendenning GA; Gnanasakthy A; Cella D
    Value Health; 2005; 8(2):117-27. PubMed ID: 15804320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer's Disease Cooperative Study.
    Patterson MB; Mack JL; Mackell JA; Thomas R; Tariot P; Weiner M; Whitehouse PJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S40-4. PubMed ID: 9236951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized Alzheimer's disease subjects.
    White HK; McConnell ES; Bales CW; Kuchibhatla M
    J Am Med Dir Assoc; 2004; 5(2):89-97. PubMed ID: 14984619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.
    Ferris SH; Mackell JA; Mohs R; Schneider LS; Galasko D; Whitehouse PJ; Schmitt FA; Sano M; Thomas RG; Ernesto C; Grundman M; Schafer K; Thal LJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S1-12. PubMed ID: 9236947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
    Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
    J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers' well-being: ALSOVA 3-year follow-up.
    Koivisto AM; Hallikainen I; Välimäki T; Hongisto K; Hiltunen A; Karppi P; Sivenius J; Soininen H; Martikainen J
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):273-83. PubMed ID: 26177825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K.
    Livingston G; Katona C; François C; Guilhaume C; Cochran J; Sapin C
    Int Psychogeriatr; 2006 Sep; 18(3):527-38. PubMed ID: 16466593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.